Leonurine Ameliorates Doxorubicin-Induced Cardiotoxicity via Endothelial STING/NF-κB/NLRP3 Inflammasome Pathway

Study Background and Research Question

Doxorubicin (DOX) is a widely used chemotherapeutic agent, but its clinical utility is limited by significant, dose-dependent cardiotoxicity that can progress to irreversible heart failure. Decades of research have focused on protecting cardiomyocytes, yet this approach has not yielded effective targeted therapies for doxorubicin-induced cardiomyopathy (DIC). The cellular and molecular mechanisms underlying the progression from initial myocardial injury to chronic dysfunction remain incompletely understood, and the contribution of non-cardiomyocyte populations—particularly cardiac vascular endothelial cells (CVECs)—to DIC pathogenesis has been largely overlooked. The reference study (Wang Jun et al., 2026) addresses whether CVECs act as key initiators of DOX cardiotoxicity and explores new therapeutic strategies targeting this cell population.

Key Innovation from the Reference Study

The central innovation of this work is the identification of CVECs as the primary cellular sensors and amplifiers of doxorubicin-induced cardiac injury. The study demonstrates that circulating DOX directly activates the cyclic GMP-AMP synthase (cGAS)–STING (Stimulator of Interferon Genes) pathway in CVECs. This triggers downstream NF-κB activation, NLRP3 inflammasome assembly, endothelial pyroptosis, and the release of pathogenic extracellular vesicles (EVs) that induce mitochondrial dysfunction in neighboring cardiomyocytes. This newly defined self-perpetuating injury loop shifts the conceptual paradigm from a cardiomyocyte-centric to an endothelial-centric view of DIC pathophysiology.

Crucially, the study identifies leonurine (LEO), a natural alkaloid from Leonurus japonicus, as a direct STING inhibitor. Structural and biochemical analyses reveal that LEO binds specifically to the TYR261 residue of STING, blocking both STING oligomerization and STING–TBK1 heterodimer formation. This dual-inhibition mechanism distinguishes LEO from other known STING inhibitors and offers a new targeted approach to interrupting the endothelial injury loop at its origin.

Methods and Experimental Design Insights

This study employed a combination of in vivo and in vitro approaches to dissect the sequence of events underlying DIC and assess the therapeutic potential of leonurine. Key methodologies included:

• Animal models of DIC: Mice received cumulative doses of doxorubicin to induce cardiomyopathy. Cardiac function was assessed by echocardiography and histopathology.
• Endothelial and cardiomyocyte co-culture systems: To model cell-cell communication and the propagation of injury signals from CVECs to cardiomyocytes.
• Molecular pathway interrogation: Pharmacological inhibitors, gene knockdown, and overexpression systems were used to dissect the roles of cGAS, STING, NF-κB, and NLRP3 pathways.
• EV isolation and functional assays: Extracellular vesicles released from DOX-injured CVECs were isolated and characterized for their ability to transfer mitochondrial dysfunction to cardiomyocytes.
• Structural and biochemical analysis: Surface plasmon resonance and mutagenesis studies mapped the interaction between LEO and the TYR261 residue of STING.

Immunohistochemistry (IHC) and immunocytochemistry (ICC) with fluorescent signal amplification were extensively used to localize protein expression and detect low-abundance signaling molecules in cardiac tissue and cultured cells.

Protocol Parameters

• Doxorubicin administration: Cumulative dosing in mice, e.g., 5 mg/kg weekly for 4 weeks, to model chronic cardiotoxicity.
• Leonurine treatment: Daily oral or intraperitoneal administration at 10–20 mg/kg, starting prior to or concurrent with DOX exposure.
• Endothelial/cardiomyocyte co-culture: Ratio and timing optimized to capture acute and chronic EV-mediated effects; typically 1:1 to 1:2, 24–48 hours post-injury.
• EV isolation: Ultracentrifugation or commercial EV isolation kits, followed by nanoparticle tracking analysis and protein marker validation.
• Immunofluorescence protocols: Employing tyramide signal amplification for low-abundance target detection, with HRP-conjugated secondary antibodies and Cy3 or comparable fluorophores for visualization.

Core Findings and Why They Matter

The study’s pivotal discovery is that CVECs, rather than cardiomyocytes, are the initial sensors of DOX-induced injury. Upon DOX exposure, CVECs activate the cGAS-STING pathway, leading to NLRP3 inflammasome assembly and pyroptotic cell death. This process is accompanied by an increased release of pathogenic extracellular vesicles, which carry damage signals to neighboring cardiomyocytes and perpetuate mitochondrial dysfunction. This mechanism establishes a self-amplifying injury loop, fundamentally revising the traditional model of DIC progression (reference study).

Leonurine interrupts this loop by directly binding the previously uncharacterized TYR261 residue on STING, thereby blocking STING oligomerization and downstream signaling. This dual mechanism not only preserves endothelial integrity but also indirectly protects cardiomyocyte mitochondria and cardiac function. These findings place endothelial STING as a high-value therapeutic target and position leonurine as a promising candidate for the prevention and treatment of DIC, with a mechanism distinct from currently available agents.

Comparison with Existing Internal Articles

While the reference study focuses on cardiovascular toxicity and innate immune signaling, it relies on advanced fluorescence microscopy detection and signal amplification to localize key pathway components in tissue and cell models. This technical need aligns closely with the workflows described in several internal resources:

• The article "Cy3 TSA Fluorescence System Kit: Ultra-Sensitive Signal Amplification" details how tyramide signal amplification (TSA) enables robust detection of low-abundance proteins and nucleic acids using HRP-catalyzed deposition of Cy3-labeled tyramide, which parallels the detection strategies required for mapping inflammatory and mitochondrial markers in DIC models.
• "Cy3 TSA Fluorescence System Kit: Next-Generation Signal Amplification" explores applications in cancer research, particularly for visualizing transcriptional regulators—another field where highly sensitive immunocytochemistry fluorescence amplification is critical.
• "Cy3 TSA Fluorescence System Kit: Unraveling Metabolic Networks" addresses the use of advanced TSA kits for mapping metabolic signaling, highlighting the cross-disciplinary relevance of ultrasensitive detection platforms for research into cell injury and signaling pathways.

Collectively, these articles underscore the technical importance of TSA fluorescence kits for the detection of low-abundance biomolecules in complex biological systems, such as those investigated in the reference DIC study.

Limitations and Transferability

Although this research provides compelling evidence for an endothelial-centered mechanism in DIC and demonstrates the unique activity of leonurine as a STING inhibitor, several limitations should be noted. First, the majority of mechanistic insights are derived from murine models and cell culture systems; extrapolation to human physiology requires further validation. The specificity and off-target effects of leonurine in vivo, particularly regarding other immune or vascular pathways, remain to be fully characterized. In addition, while the study elegantly dissects the sequence of molecular events from CVEC injury to cardiomyocyte dysfunction, it does not fully address the heterogeneity of endothelial populations in the human heart or the influence of comorbidities (e.g., diabetes, hypertension) on DIC susceptibility.

Transferability to clinical practice will depend on confirming these findings in human tissues and evaluating leonurine’s pharmacokinetics, safety, and efficacy in larger animal models and eventually in patients. Nonetheless, the work establishes a new research direction focused on upstream endothelial intervention, with broad implications for the design of cardioprotective strategies against chemotherapeutic toxicity.

Research Support Resources

For experimental workflows requiring ultrasensitive detection of low-abundance proteins, nucleic acids, or signaling intermediates—such as those described in this DIC study—researchers can leverage the Cy3 TSA Fluorescence System Kit (SKU K1051) from APExBIO. This kit utilizes tyramide signal amplification technology and a Cy3 fluorophore (excitation 550 nm, emission 570 nm), facilitating robust signal amplification in immunohistochemistry, immunocytochemistry, and in situ hybridization assays. Integrating such TSA fluorescence kits into cardiac, vascular, or immunology research supports the high-sensitivity visualization of key molecular events described in the reference work.